24-Week Open Label Extension to a Randomized, 6-Week Double Blind, Placebo Controlled Study, to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROSÂ® Paliperidone in the Treatment of Geriatric Subjects With Schizophrenia